Versartis, Inc. (VSAR) Raised to Buy at BidaskClub

Versartis, Inc. (NASDAQ:VSAR) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday, July 24th.

VSAR has been the topic of several other reports. Canaccord Genuity set a $28.00 target price on Versartis and gave the stock a “buy” rating in a report on Sunday, May 28th. Cantor Fitzgerald assumed coverage on Versartis in a report on Thursday, May 4th. They set an “overweight” rating and a $34.00 target price on the stock. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. Piper Jaffray Companies boosted their target price on Versartis from $22.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, April 4th. Finally, ValuEngine upgraded Versartis from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $25.43.

Shares of Versartis (NASDAQ VSAR) traded up 0.61% during trading on Monday, reaching $16.60. The company had a trading volume of 148,872 shares. The company’s market capitalization is $590.59 million. The stock’s 50-day moving average price is $17.59 and its 200-day moving average price is $18.05. Versartis has a 52 week low of $9.05 and a 52 week high of $24.00.

Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.20. On average, equities analysts expect that Versartis will post ($3.25) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Versartis, Inc. (VSAR) Raised to Buy at BidaskClub” was posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/versartis-inc-vsar-upgraded-to-buy-by-bidaskclub-2-updated-updated-updated.html.

Several hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its stake in Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock valued at $94,096,000 after buying an additional 253,632 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in Versartis during the first quarter valued at approximately $4,117,000. Renaissance Technologies LLC raised its stake in shares of Versartis by 334.6% in the first quarter. Renaissance Technologies LLC now owns 214,700 shares of the biopharmaceutical company’s stock worth $4,584,000 after buying an additional 165,300 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Versartis by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after buying an additional 118,894 shares during the last quarter. Finally, ClariVest Asset Management LLC purchased a new stake in shares of Versartis during the first quarter worth about $2,480,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply